In Modern Healthcare’s article, “House Passes Bipartisan FDA User Fee Bill,” Partner David Rosen discussed the impact of new legislation passed in the House of Representatives that reauthorizes the FDA’s ability to collect user fees from drug and device makers.
“It gives the FDA predictable resources and allows the industry to have a better understanding of when the FDA will complete reviews, which is very important,” Rosen said.
(Subscription may be required to read)
“It gives the FDA predictable resources and allows the industry to have a better understanding of when the FDA will complete reviews, which is very important,” Rosen said.
(Subscription may be required to read)
People
Related News
July 24, 2025
In the News
Foley's Trial Team Featured Following Landmark Victory in Texas Trade Secret Case
Foley & Lardner LLP’s recent landmark appellate victory in a Texas trade secrets case is featured in the Texas Lawyer article, "Ruling Sets Precedent for Employment, Trade Secrets, Fiduciary Duty."
July 24, 2025
In the News
Gregory Husisian and David Simon on Tariff Evasion – 'Huge money at stake'
Foley & Lardner LLP partners Gregory Husisian and David Simon detailed the rise and risks of tariff evasion in the POLITICO article, "As Trump raises tariffs, companies find ways to cheat — and risk getting caught."
July 23, 2025
In the News
Aaron Maguregui on AI Scribes in Health Care – 'Technically, it's a third party listening'
Foley & Lardner LLP partner Aaron Maguregui shared insights on the growing applications for artificial intelligence across health care in the healthleaders article, “Is Your AI Scribe HIPAA-Compliant?“